A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors.

Trial Profile

A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2013

At a glance

  • Drugs IMGN 388 (Primary)
  • Indications Breast cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 22 May 2012 Actual patient number is 60 as reported by ClinicalTrials.gov.
    • 22 May 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 22 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top